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Abstract
Background: Diabetes has already become a threat to the nation and the individual due to its high prevalence
rates and high medical expenses. Therefore, preventing diabetes at an earlier stage is very important. Despite
advances in antidiabetic agents, we have not yet achieved any satisfying results in treating diabetes. Among
various treatments, medicinal herbs and supplements for diabetes are reported to show generally good efficacy
and safety data. In particular, PURIAM110, a compound from orange fruits and mulberry leaves, is supposed to
prevent the progress of type II diabetes mellitus and improve diabetic symptoms. This is the first reported pilot
study about the protective effect of the orange fruits and mulberry leaves mixture against pre-diabetes on Korean
adults. Based on these positive results of herb-derived components, extended studies of dietary supplements have
to be done to suggest confirmative evidences.
Methods/Design: The efficacy and safety study of PURIAM110 is a double-blinded, placebo-controlled,
randomized, and multi-center clinical trial. A total of 45 subjects will participate in this study for 6 weeks.
Discussion: The present protocol will confirm the efficacy and safety of PURIAM110 for pre-diabetes, suggesting
more basic knowledge to conduct further randomized controlled trials (RCT). In addition, PURIAM110 can be an
alternative dietary supplemental remedy for diabetes patients.
Trial Registration: ISRCTN: ISRCTN44779824
Background
Pre-diabetes is a condition of potential diabetes mellitus
with an increased risk of developing type 2 diabetes
[1,2]. In other words, it is a state of either impaired fast-
ing glucose (IFG) or impaired glucose tolerance (IGT).
Pre-diabetes is asymptomatic in many occasions, but
once it develops into type 2 diabetes, it makes patients
suffer from polydipsia, polyuria, polyphasia, unusual
weight loss, and extreme fatigue [3]. Unmanaged
chronic diabetes mellitus affects quality of life and
induces life-threatening diabetes-associated complica-
tions [4,5]. Its mortality rate cannot be ignored in
Korea, becoming the fourth leading cause of death by
2030 [6]. According to the Korean National Health and
Nutrition Survey (KNHNS) 2001, prevalence rates of
diabetes were 1.4 million (8.1%) in Korean men and 1.3
million (7.5%) in Korean women. Nowadays, it is
reported that about 308 million people worldwide are
having impaired glucose tolerance (IGT) and among
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exact figures of Korean pre-diabetes patients and dia-
betes progressing rates were not reported [4], we can
deduce from the above numerical statement that a
considerable population must be at the status of poten-
tial diabetes. Socioeconomic expenditures are also
high, at 193 million won per year for medication [4,9].
Therefore, preventing and treating efforts for the non-
insulin taking patients in the stage of pre-diabetes and
diabetes are urgently needed to lift the burden from
both the nation and patients [10]. Even though novel
remedies have been produced unceasingly, most of
them seem to be often ineffective for this disease
[11,12]. Meanwhile, dietary supplements are known to
be relatively effective in treating diabetes, with few
adverse effects [13-15]. Among 400 reported herbal
medicines for diabetes [16], recent studies suggests
that bitter oranges and mulberry leaves have antidia-
betic effects. PURIAM110, a compound made from
orange fruits and mulberry leaves (patent application
no. 10-2006-0020040), is expected to prevent the pro-
gress to the early stage of diabetes mellitus, safely
[17,18]. Bitter orange is a dried, immature fruit of
Citrus aurantium L., used from ancient times to
remove the stagnation and distension in hypochondriac
regions [19,20]. Like other herbal components, its
mechanism of action seems to be complex though, the
fruit has been identified to produce antihyperglycemic
activity. Mulberry leaf is a dried leaf of Morus indica
L., which also shows hypoglycemic properties [21,22].
It has been prescribed widely to dispel wind-heat and
heat in the lung [23,24]. Relying on pathophysiologic
mechanisms from traditional Korean medicine, dia-
betes can be caused when there is heat in the lung or
ad e f i c i e n c yo fe n e r g y( Y a n gq i )a n db o d yf l u i d .T h e r e -
fore, bitter orange’s qi driving activity and mulberry
leaf’s heat dispelling function in the lung can be
applied to play an antidiabetic role.
Despite the advantages of herb-derived supplements,
few RCTs have been conducted [8,25], and the bitter
oranges and mulberry leaves compound is not an excep-
tion. Further trials of dietary supplements have to be
done to suggest confirmative evidence.
The aim of this study is to evaluate the efficacy and
safety of the PURIAM110, a dietary supplement for the
treatment of patients with pre-diabetes and diabetes
mellitus non-insulin dependent stage [26]. This paper is
the first pilot study with orange fruits and mulberry
leaves on Korean adults who are at the status of pre-
diabetes and diabetes mellitus not in the insulin requiring
stage. The results of this study will give us the clinical of
biochemical parameters, such HbA1c, fructosamine, fast-
ing glucose and 2-h OGTT glucose between the placebo
and PURIAM110 groups. On the basis of the results, we
can suggest the optimal design, precise sample size, and
primary outcome for a further large scale RCT.
Methods/design
Objectives & Hypothesis
Objectives
The primary objective of this pilot study is to assess the
efficacy and safety of PURIAM110 on non-insulin taking
Korean adults in the stage of pre-diabetes and diabetes
mellitus.
The secondary objective is to estimate the precise
sample size and primary endpoint required for the large
scale RCT.
Hypothesis
We hypothesize that glucose concentration of pre-
diabetes and diabetes mellitus who are treated with PUR-
IAM110 will be lower than that of the control group.
Also, we expect that other diabetes related parameters
(total cholesterol, triglyceride, and LDL cholesterol) to be
improved and the symptoms to be normalized in the
treatment group.
Study design
This is a 6-week, double-blinded, placebo-controlled,
randomized, and multi-center clinical trial assessing the
efficacy and safety of PURIAM110.
The study has been conducted in two Oriental Medi-
cal Hospitals in Korea from December 2006.
Figure 1 provides an overview of the study.
Population
The Korea Food & Drug Administration (KFDA)’sr u l e
recommends including not only healthy group but also
Follow up (if needed) Follow up (if needed)
Visit 5 (8th week, day 56)
PURIAM110 group
460±10mg/1 capsule, 3 capsules/time, 2 times/day
total 6 weeks
PURIAM110 group
460±10mg/1 capsule, 3 capsules/time, 2 times/day
total 6 weeks
Placebo group
460±10mg/1 capsule, 3 capsules/time, 2 times/day
total 6 weeks
Placebo group
460±10mg/1 capsule, 3 capsules/time, 2 times/day
total 6 weeks
Visits and clinical measurements, medication for 6 weeks Visits and clinical measurements, medication for 6 weeks
1. Visit 2 (0 week, day 0-baseline)
2. Visit 3 (3rd week, day 21)
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Screening for eligible individuals Screening for eligible individuals
Visit 1 (-1 week, -7 day) Visit 1 (-1 week, -7 day)
randomization randomization
Figure 1 Study flowchart. Summary of the study flow.
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dietary supplement trials. Therefore, we included pre-
diabetes status, and diabetes mellitus non-insulin depen-
dent stage Korean adults, aged 18 to 65. The detail
inclusion and exclusion criteria are described in Table 1
and Table 2.
Inclusion and exclusion criteria
Inclusion criteria
Inclusion criteria are as follows (Table 1).
Exclusion criteria
Exclusion criteria of PURIAM110 trial are summarized
in Table 2.
Suspension criteria
￿ Administration of forbidden medicine.
￿ Subject’s demand to discontinue the study.
￿ Serious adverse events (AE) or unusual changes in
clinical test results.
￿ Principal investigator’s decision to terminate the
study (low rates of compliance, complications, or unable
to sustain the study for various reasons).
Sample size
We had difficulties in determining adequate sample size,
as preliminary studies were insufficient. So we adopted a
pilot study design.
Two points had to be considered in deciding the sam-
ple size. One was the special condition of herb-derived
dietary supplements regulatory law in Korea, and another
was limited research fund. Since herbs have historical
efficacy and safety profile in Korea, KFDA regulates diet-
ary supplements under a different rule, compared to con-
ventional drugs. In other words, as the efficacy and safety
of herbal products have been clinically validated for a
long time, the regulatory authorities have lightened
restrictions, such as minimizing sample size. We have
planned the dietary supplement study according to this
KFDA rule. The KFDA rule prescribes that when design-
ing a dietary supplements trial, the sample size has to be
a minimum 30 per group. Therefore we first fixed the
number of the subjects in the treatment group as 30.
As the research funding was restricted, we plan to
allocate 15 individuals for the placebo group. When
sample size is inevitably restricted, it is considered to be
more ethical by the KFDA to set more subjects in the
test group than in the control group. In conclusion, a
total of 45 subjects will be recruited in this pilot study.
Randomization
The study subjects will be randomly assigned to either
PURIAM110 or placebo group at a ratio of 2:1, accord-
ing to the ‘random number table’ generated by SAS soft-
ware package (SAS institute, Inc, Carey, NC, USA,
version 8.2).
Blinding
The study drugs are double blinded to both investigator
and subject. The contract research organization (CRO;
Kyung Hee University, Center for Clinical Research and
Genomics) of the sponsor, labels the investigational
drugs by the randomization code number. The labeled
experimental products will be provided to the trial sites
by the CRO.
Interventions
Treatment drug
PURIAM110 is a 460 mg hard gelatin capsule, contain-
ing dried powder of bitter oranges and mulberry leaves
Table 1 Inclusion criteria. Inclusion criteria of the
PURIAM110 trial
Inclusion criteria
1. Both gender between the ages of 18-69 years, eligible for study
through screening test prior to the enrolment.
2. Able and willing to perform the study protocol and participate
throughout the entire trial period(Screening, baseline, 3, 6 weeks,
follow up(if needed)).
3. Participants who understood the risks and benefits of the study
and signed a written informed consent.
4. Among individuals not under diabetes mellitus treatment, whose
random glucose concentration is 110~250 mg/dL measured with
Accu-Chek
®(Roche, Germany) glucometer within 3 weeks prior to
participation.
4.1. fasting plasma glucose concentration is 100-190 mg/dL or
4.2. 2- hour plasma glucose concentration* is 130-250 mg/dL
(* venous plasma glucose 2-hour after ingestion of 75 g oral
glucose load; DIASOL-S LIQ. [Glucose] Taejoon Pharm.)
Table 2 Exclusion criteria. Exclusion criteria of the
PURIAM110 trial
Exclusion criteria
1. Presently using other blood glucose level controlling agents.
2. History of allergy to the herbal products (bitter oranges and
Mulberry leaves) or allergic diseases such as asthma.
3. Medication (within the last 1 month or during the study) which
would affect the study results.
4. Daily intake of alcoholic beverages.
5. Smokers consuming more than 1 pack/day.
6. Presently having acute diseases or other untreated illness requiring
treatment.
7. Impaired hepatic or renal functions.
8. Pregnant, breast feeding status or female of reproductive age, not
using proper contraception.
9. Participant in other clinical trials or a blood donor, within the past
1 month.
10. History of severe disease or any condition, in the investigator’s
opinion, that would endanger the individual’s safety or affect the
study result.
11. Patients diagnosed as type I and type II diabetes mellitus(insulin
requiring stage).
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extraction of bitter oranges and mulberry leaves 1:1
mixture followed by spray drying. The raw material
extract is provided by SunTen pharmaceutical company
(SUN TEN PHARMACEUTICAL Co., LTD.) in Taiwan.
Constituents of PURIAM110
The constituents of PURIAM110 are in Table 3.
Placebo
The placebo will contain the lactose. And the placebo
will be manufactured to have a similar appearance,
shape, weight (460 ± 10 mg/1 capsule), taste, and color
with PURIAM110 [27].
Directions
The subjects will be prescribed for total 6 weeks, 2
times per day (3 capsules before breakfast and 3 cap-
sules before dinner). Participants will take total 6 cap-
sules daily, with a dose of 2,760 mg (460 ± 10 mg/1
capsule × 6 capsules).
Study groups
1. Treatment group: PURIAM110.
2. Control group: placebo.
Study period
The study period will be of 42 days (total 6 weeks). The
visits and the evaluations will be done at the screening
(visit1), 0th day (visit2; baseline), 21th day (visit3; 3rd
week), and 42nd day (visit4; 6th week). 56th day is a fol-
low up (if needed).
Outcomes
Efficacy assessment index
Primary outcome index 1. Biochemical parameters:
1.1. HbA1c
1.2. Fructosamine
1.3. Fasting glucose
1.4. 2-h OGTT glucose
1.5. Fasting insulin
1.6. Total cholesterol
1.7. Triglyceride
1.8. Low density lipoprotein (LDL) cholesterol
Secondary outcome index 1. Diabetes symptoms*
1.1. polydipsia
1.2. polyuria(frequent urination)
1.3. polyphasia
1.4. fatigue
2. Other clinically significant parameters**
3. Anthropometric parameters:
3.1. body weight(kg)***
3.2. waist circumference(WC, cm)
3.3. hip circumference(HC, cm)
The primary and secondary outcomes will be mea-
sured at the 0th day (visit2; baseline), the 21th day
(visit3; 3rd week), and the 42nd day (visit4; 6th week)
during the treating period. And, when necessary, the
outcomes will be assessed at the 56th day (follow-up).
The changes between the 0th day (visit2; baseline) and
the 42nd day (visit4; 6th week) measurements will be
analyzed for the primary outcome indexes. For the sec-
ondary outcomes, a visual analogue scale (VAS) will be
used to detect the improvement of diabetic symptoms
(*). When the scale has improved more than two grades
or a patient has recovered completely from these
symptoms, it will be evaluated as ‘effective’. For other
categories (**), we will assess whether these parameters
have normalized or not. Measured weight minus 0.5 kg
(participant’s garment weight) will be recorded as the
subject’s true weight (***).
Safety assessment index
All informations including vital signs, general medical
examinations, laboratory test results, and adverse events
will be recorded for the safety assessment.
Procedures
Recruitment
Subjects will be recruited through two routes. Patients
who visit the trial hospitals and meet the criteria will be
recommended by a physician in charge. Those who see
the trial poster on bulletin boards will visit the trial site
voluntarily.
Study schedule & test items per visit
The detailed items which will be measured at every visit
are described in Table 4.
Measurement tools
Visual analogue scale (VAS)
A1 0c mV A S( r a n g i n gf r o m0c ma sn os y m p t o mt o
10 cm as the maximum symptom) will be used to assess
diabetic symptoms (polydipsia, polyuria, polyphasia, and
fatigue) improvement during treatment term.
Anthropometric measurements
The items will be measured with a standard operating
procedure (SOP) by the well-trained physicians. All par-
ticipants will be measured in light garments (estimated
approximately 0.5 kg) and bare feet. The waist circum-
ference (WC: recorded to the nearest 0.1 cm) will be
taken 2.5 cm above the umbilicus at the upright posi-
tion. The hip circumference (HC: to the nearest 0.1 cm)
Table 3 Constituents of PURIAM110. Constituents of the
PURIAM110
PURIAM110 (460 mg/1 hard gelatin capsule)
bitter oranges (zhi shi, Fructus Aurantii; the unriped fruits of Citrus
aurantium L.)
mulberry leaves (sang ye, the dried leaf of Folium Mori)
Sodium Silica Aluminate (lubricants)
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part of the hip.
Questionnaire for the Sasang Constitution Classification II
(QSCC II)
A QSCC II is a questionnaire which categorizes a person
into four types of constitution by its characteristics, in tra-
ditional Korean medicine. We will use this questionnaire
to classify Korean pre-diabetes and diabetes (not insulin
requiring stage) patients. Also we will apply this question-
naire to evaluate the association between the pre-diabetes
susceptibility and the patient’s constitution. Moreover, we
will use this to assess which constitution responds well to
PURIAM110 [28].
Compliance calculation
The researchers should provide the investigational drug
to the randomized participants in time and explain med-
ication to them. Compliance of subjects will be evalu-
ated by the below formula. Subjects are asked to return
remaining drugs.
Compliance(%) = [(distributed drugs-remained drugs)/
distributed drugs] ×100
Table 4 Study schedule. A brief study schedule at every visit
Screening*
Visit 1
Baseline
Visit 2
Visit 3 Visit 4 Follow up
(Visit 5)
D-21
~D-1
D0
Week 0
D21
Week 3
D42
Week 6
D56
Week 8
Informed consent form ●
Demographic information
taking
1
●
Medical history taking ●
Finger-prick
blood glucose testing
●
QSCC II
2 ●
Inclusion/exclusion
criteria check
●
Physical examination
3 ●● ● ●
Vital sign measurement
4 ●● ● ●
Laboratory test
5 ●● ● ●
VAS
6 ●● ● ●
Electrocardiogram(ECG) ●●
Concomitant drugs check ●● ● ●
Treating physician
examination
7
●● ● ●
Adverse event monitoring ●● ●
Compliance checking ●
Study drug distribution ●●
Smoking, drinking, coffee
taking status
8
●
Diet, physical exercise
Counseling
8
●●
●: Item need to be carried out during the visit.
*required to fast from 10 p.m. the day before the test prior to the blood sample collection.
1sex, date of birth, age, contact address and phone number.
2Questionnaire for the Sasang Constitution Classification II.
3body weight(kg), height(cm), waist circumference(cm), hip circumference(cm).
4blood pressure(mmHg), pulse(/min), body temperature(°C).
5blood test (WBC, RBC, hemoglobin(HGB), hematocrit(HCT), platelet count(PLT), AST, ALT, g-GTP, total bilirubin, albumin, total protein, total cholesterol,
triglyceride, HDL cholesterol, BUN, creatinine, glucose(fasting), 2h-OGTT glucose, HbA1c, fructosamine, insulin(fasting)), urine test.
6visual analogue scale: polydipsia, polyuria, polyphasia, fatigue.
7includes present illness, past history taking.
8risk factors such as smoking, alcohol drinking, severe exercise and other drug intake will be managed strictly.
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Efficacy analysis
All analyses in this study will be based on both intention-
to-treat (ITT) and per protocol (PP) method. The ITT
method will include all randomized subjects who made
at least one next visit. The participants who have com-
pleted the 6-week treatment without major protocol vio-
lations and kept compliance rate over 80% will be
analyzed by the pp (per protocol) method. The continu-
ous variables will be summarized as mean±SD (standard
deviation) and the categorical variables will be described
in frequency and percent. For the primary and secondary
outcome variables, the mean differences between before
(visit 2; baseline) and after the treatment (visit 4) values
will be compared using the paired t-test or Wilcoxon
test, in each group. The baseline characteristics will be
compared by either the Student t-test for the continuous
variables or c
2-test for the categorical data (alternatively,
Fisher’s exact test will be used if the expected value is
less than 5 or McNemar’s test for non-normal distribu-
tion data). The efficacy of PURIAM110 will be assessed
by using the independent t-test (when normality assump-
tion is satisfied, alternatively Mann-Whitney test will be
used). All analyses will be based on a two-sided test at a
5% significance level. With values of p < 0.05 will be con-
sidered statistically significant. SPSS for windows version
12.0 (SPSS Inc., Chicago, Illinois) will be used for ana-
lyses. For missing values, ‘Last Observation Carried For-
ward (LOCF)’ method will be applied.
Safety analysis
In the safety analysis, it will include the subjects who
were both randomized and treated with the investiga-
tional drug at least once. There will be stratification by
the institution and the adverse event symptom.
Adverse event (AE) reporting
A l lA Em u s tb eo b s e r v e da n dd o c u m e n t e di nt h eC R F
AE form. When AE happens, researchers must report it
to both IRB and regulatory authorities within 24 hours.
Data collection
After filling out the CRF, data collection will be performed
according to the standard operating procedures (SOPs), by
the trained clinical research associates (CRAs).
Data management and monitoring
For data accuracy and trial quality, monitoring and data
management will be carried out by the authorized con-
tract research organization (CRO), Center for Clinical
Research and Genomics (CCRG), Seoul, Korea.
Ethical approvals
The study has been accepted by the Institutional Review
Board (IRB) of two hospitals (Institutional Review Board
o ft h eK y u n gH e eU n i v e r s i t yO r i e n t a lM e d i c a lC e n t e r
approved on the 21th of November 2006 (ref: KOMC
IRB 2006-14), and Institutional Review Board of the
Kyung Won Gil Oriental Medical Hospital approved on
the 25th of October 2006(ref: 06-101)). Informed con-
sent form will be provided to each individual prior to
the enrolment. The research will be performed in com-
pliance with the Helsinki Declaration and the Good
Clinical Practice (GCP) Guidelines.
Discussion
In this paper, we have suggested the clinical trial design of
a pre-diabetes treating dietary supplement. This pilot study
will be the groundwork for the larger scale RCT. To draw
confirmative conclusion about the therapeutic efficacy and
safety of pre-diabetes supplements, a full-scale RCT has to
be done. To proceed with the trial, two criteria must be
decided through this study. First, the adequate sample size
has to be calculated. As there were no published studies
with similar outcomes, we had difficulties in obtaining the
mean and variation estimates for the study. Therefore, we
designed a pilot trial to figure out the mean and standard
deviation. Besides, this study result will also provide a mag-
nitude of the clinically significant treatment effect. With
these estimates, we will be able to compute the exact sam-
ple size of the larger multicenter study. Second, the pri-
mary endpoint has to be fixed. The current preclinical
study results suggest that bioflavonoids, hesperidin, and
naringin, which are contained in mulberry leaves and bitter
oranges, prevent not only hyperglycemia but hyperlipide-
mia in type-2 diabetic animals [17,18,21,22,29,30]. Based
on these consequences, we decided to include lipid profile
(total cholesterol, triglyceride, LDL cholesterol) indexes, in
addition to the glucose related parameters (HbA1c, fructo-
samine, fasting glucose, 2-h OGTT glucose, fasting insulin).
Among the glucose and the lipid related parameters, we
will decide the primary outcome for a large scale trial
according to the result of this study. Furthermore, as anti-
diabetic agents show ethnic differences, PURIAM110 has
to be verified by more various groups.
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